# A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

> **NCT01940497** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 240 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Docetaxel
- **DRUG:** Paclitaxel
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT01940497
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-15
- **Primary completion:** 2016-04-05
- **Final completion:** 2018-03-27
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2020-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01940497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01940497, "A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01940497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*